Thrombolytic and cytoprotective therapies for acute ischemic stroke: A clinical overview

Drugs of Today

Volumn 32, Issue 7, 1996, Pages 573-592

  Önal, Mehmet Zülküf ^a,b   Fisher, Marc ^c  

^a AKDENIZ UNIVERSITY   (Turkey)

^b Med Center of Central Massachusetts   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; APTIGANEL; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CITICOLINE; DARODIPINE; DIZOCILPINE; ELIPRODIL; FIBRINOLYTIC AGENT; FLUNARIZINE; FOSPHENYTOIN SODIUM; GANGLIOSIDE GM1; GAVESTINEL; HEPARIN; ISRADIPINE; LIFARIZINE; LUBELUZOLE; MAGNESIUM; NIMODIPINE; PROPENTOFYLLINE; PROUROKINASE; REMACEMIDE; REPINOTAN; SIPATRIGINE; STREPTOKINASE; TIRILAZAD; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE;

ANGIOGRAPHY; BLEEDING; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROPROTECTION; REPERFUSION INJURY; REVIEW;

EID: 0029729256     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (182)

1. Fisher, M., Prichard, J.W., Warach, S. New magnetic resonance techniques for acute ischemic stroke. JAMA 1995, 274: 908-11.
2. Silver, B., Weber, J., Fisher, M. Review: Medical therapy for ischemic stroke. Clin Neuropharmacol 1996, 19: 101-28.
3. Meldrum, B.S. Cytoprotective therapies in stroke. Curr Opin Neural 1995, 8: 15-23.
4. Marder, V.J., Sherry, S. Thrombolytic therapy: Current status. New Engl J Med 1988, 318: 1512-85.
5. Verstraete, M. Biochemical and clinical aspects of thrombolysis. Semin Hematol 1978, 15: 35.
6. Marder, V.J. Thrombolytic therapy: Overview of results in major vascular occlusions. Thromb Haemostas 1995, 74: 101-5.
7. Lijnen, H.R., Collen, D. Fibrinolytic agents: Mechanisms of activity and pharmacology. Thromb Haemostas 1995, 74: 387-90.
8. Mori, E. Fibrinolytic recanalization therapy in acute cerebrovascular thromboembolism. In: Thrombolytic Therapy in Acute Ischemic Stroke. Hacke, W., del Zoppo, G.J., Hirschberg, M. (Eds.). Springer-Verlag: Berlin, Heidelberg 1991, 137-46.
9. Siesjö, B.K. Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanisms of damage and treatment. J Neurosurg 1992, 77: 337-54.
10. Macabasco, A.C., Hickman, J.L. Thrombolytic therapy for brain attack. J Neurosci Nurs 1995, 27: 138-49.
11. del Zoppo, G.J., Hamann, G., Fitridge, R., Okada, Y. Thrombolytic therapy. In: Stroke Therapy. Fisher, M. (Ed.). Butterworth-Heinemann: Boston 1995, 291-313.
12. del Zoppo, G.J. Acute stroke on the threshold of a therapy? New Engl J Med 1995, 333: 1632-3.
13. Overgaard, K. Thrombolytic therapy in experimental embolic stroke. Cerebrovasc Brain Metab Rev 1994, 6: 257-86.
14. Brott, T.G., Haley, E.C. Jr., Levy, D.E. et al. Urgent therapy for stroke. Part I. Pilot study of tissue PA administered within 90 ms. Stroke 1992, 23: 632-40.
15. Chopp, M., Zhang, R.L. Animal modeling for developing stroke. In: Stroke Therapy. Fisher, M. (Ed.). Butterworth-Heinemann: Boston 1995, 117-34.
16. Trembly, B. Clinical potential for the use of neuroprotective agents: A brief overview. Ann NY Acad Sci 1995, 765: 1-20.
17. Bando, H., Okada, K., Matsuo, O. Thrombolytic effect of pro-UK in-vitro. Fibrinolysis 1987, 1: 169-76.
18. Wagstaff, A.J., Gillis, J.C., Goa, K.L. Alteplase: A reappraisal of its pharmacology and therapeutic use in vascular disorders other than AMI. Drugs 1995, 50: 289-316.
19. Kline, E.M. Pharmacologic review of thrombolytic agents. Crit Care Nurs Clin N Amer 1990, 2: 613-27.
20. White, W.F., Barrow, G.H., Mozen, M.M. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966, 5: 2160-9.
21. Bernik, M.B., Kwaan, H.C. PA activity in cultures from human tissues. An immunological and histochemical study. J Clin Invest 1969, 48: 1740-53.
22. Fletcher, A.P., Alkjaersig, N., Sherry, S., Genton, E., Hirsh, J., Bachmann, F. The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 1965, 65: 713-31.
23. Stump, D.C., Mann, K.G. Mechanisms of thrombus formation and lysis. Ann Emergency Med 1988, 17: 1138-47.
24. Matsuo, O. New thrombolytic agents: Basic development. In: Thrombolytic Therapy in Acute Ischemic Stroke III. Yamaguchi, T., Mori, E., Minematsu, K., del Zoppo, G.J. (Eds.). Springer: Tokyo 1995, 182-7.
25. Verstraete, M., Collen, D. Thrombolytic therapy in the eighties. Blood 1986, 67: 1529-41.
26. Gunzler, W.A., Steffens, G.J., Otting, F., Buse, G., Flohe, L. Structural relationship between human high and low molecular mass urokinase. Hoppe Seylers Z Physiol Chem 1982, 363: 133-41.
27. Lijnen, H.R., Zamarron, C., Blaber, M., Winkler, M.E., Collen, D. Activation of plasminogen by pro-UK. I. Mechanism. J Biol Chem 1986, 261: 1253-8.
28. Bobbins, K.C., Summaria, L , Hsieh, B., Shah, R.J. The peptide chain of human plasmin. J Biol Chem 1967, 242: 2333-42.
29. Rijken, D.C. Structure/function relationships of t-PA. In: Tissue-Type PA (t-PA): Physiological and Clinical Aspects, Vol. 1. Klurt, C. (Ed.). CRC Press: Boca Raton 1988, 101-22.
30. Bovill, E., Stump, D., Tracy, R. et al. for the TIMI Investigators. Dose response relationship of t-PA infusion to induction of systemic fibrinogenolysis in the thrombolysis in myocardial infarction. (TIMI) trial. Blood 1987, 70 (Suppl. 1): Abst 367A.
31. Eisenberg, P.R., Sherman, L.A., Tiefenbruun, A.J., Ludbrook, P.A., Sobel, B.E., Jaffe, A.S. Sustained fibrinolysis after administration of t-PA despite its short half-life time in the circulation. Thromb Haemost 1987, 57: 35-40.
32. Borer, J.S. T-PA and the principals of drug approval. New Engl J Med 1987, 317: 1659-61.
33. Castellino, F.J. A unique enzyme protein substrate modifier reaction: Plasmin/SK interaction. Trends Biochem Sci 1979, 4: 1-5.
34. Monk, J.P., Heel, R.C. Anisoylated plasminogen streptokinase activator complex (APSAC): A review of its mechanism of action, clinical pharmacology and therapeutic use in AMI. Drugs 1987, 34: 25-49.
35. Martin, U., Sponer, G., Strein, K. Evaluation of thrombolytic and systemic effects of the novel recombinant PA BM06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992, 19: 433-40.
36. Matsuo, O., Okada, K., Fukao, H. et al. Thrombolytic properties of staphylokinase. Blood 1990, 76: 925-9.
37. Apprill, P.G., Ashton, J., Guerrero, J. et al. Ancrod decreases the frequency of cyclic thrombolysis following acute coronary thrombosis. Am Heart J 1987, 113: 898.
38. Bell, W.B. Defibrinogenating enzymes. In: Hemostasis and Thrombosis. Colman, R.W., Hirsch, J., Marder, V.J., Salzman, E.W (Eds.). Lippincott: Philadelphia 1987, 886.
39. Soutar, R.L., Ginsberg, I.S. Anticoagulant therapy with ancrod. Crit Rev Oncol Hematol 1993, 15: 23-33.
40. Polak, V.E., Glas-Greenwalt, P., Olinger, C.P., Wadhwa, N.K., Myre, S.A. Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990, 299: 319-25.
41. Demers, C., Ginsberg, J.S., Brill-Edwards, P. et al. Rapid anticoagulation using ancrod for heparin induced thrombocytopenia. Blood 1991, 78: 2194-7.
42. Lowe, G.D.O. Defibrination blood flow and blood rheology. Clin Hemorheol 1984, 4: 15-28.
43. Yuh, W.T.C., Maeda, M., Wang, A.M. et al. Fibrinolytic treatment of acute stroke: Are we treating reversible cerebral ischemia? AJNR 1994, 16: 1994-2000,
44. Sussman, B.J., Fitch, T.S.P. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 1958, 167: 1705-9.
45. Zeumer, H., Hundgen, R., Ferbert, A., Ringelstein, E.B. Local intra-arterial fibrinolytic therapy in accessible internal carotid occlusion. Neuroradiology 1984, 26: 315-7.
46. del Zoppo, G.J., Ferbert, A., Otis, S. et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke 1988, 19: 307-13.
47. Hacke, W., Zeumer, H., Ferbert, A., Bruckmann, H., del Zoppo, G J. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebro-basilar occlusive disease. Stroke 1988, 19: 1216-22.
48. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of SK, aspirin and combination of both in treatment of acute ischemic stroke. Lancet 1995, 346: 1509-14.
49. Hommel, M., Boissel, J.P., Cornu, C. et al. for the MAST Study Group. Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet 1995, 345: 57.
50. Donnan, G.A., Hommel, M., Davis, S.M., McNeil, J.J. for the Steering Committees of the ASK and MAST-E trials. Streptokinase in acute ischemic stroke. Lancet 1995, 346: 56.
51. Donnan, G.A., Davis, S.M., Chambers, B.R. et al. Trials of Streptokinase in severe acute ischemic stroke. Lancet 1995, 345; 578-9.
52. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with Streptokinase in acute ischemic stroke. New Engl J Med 1996, 335: 145-50.
53. Haley, E.C. Jr., Levy, D.E., Brott, T.G. et al. Urgent therapy for stroke. Part II. Pilot study of tissue PA administered within 91-180 ms from onset. Stroke 1992, 23: 641-5.
54. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue PA for acute ischemic stroke. New Engl J Med 1995, 333: 1581-7.
55. Hacke, W., Kaste, M., Fieschi, C. et al. Intravenous thrombolysis with recombinant tissue PA for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274: 1017-25.
56. Kaste, M., Overgaard, K., del Zoppo, G. et al. for the ECASS Study Group. Who benefits and who suffers from Lv. recombinant tissue plasminogen activator in ischemic hemispheric stroke? Stroke 1996, 27: Abst 164A.
57. Fisher, M., Pessin, M.S., Furian, A.J. ECASS: Lessons for future thrombolytic stroke trials. JAMA 1995, 274: 1058-9.
58. Trouillas, P., Nighoghossian, N., Getenet, J.C. et al. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlations of outcome with clinical and radiological data. Stroke 1996, 27: 882-90.
59. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute brain infarction. Stroke 1994, 25; 1755-9.
60. 6McNamara, T.O., Fischer, J.R. Thrombolysis of peripheral arterial and graft occlusions: Improved results using high-dose urokinase. AJR 1985, 144: 769-75.
61. Clark, W.M., Barnwell, S.L. Endovascular treatment for acute and chronic brain ischemia. Curr Opin Neurol 1996, 9: 62-7.
62. Higashida, R.T., Halbach, V.V., Dowd, C.F. et al. Intravascular balloon dilation therapy for intracranial arterial vasospasm: Patient selection, technique and clinical results. Neurosurg Rev 1992, 15: 89-95.
63. Chapman, A.B., Rubinstein, D., Hughes, R. et al. Intracranial aneurysms in autosomal-dominant polycystic kidney disease. New Engl J Med 1992, 327: 916-20.
64. Mori, E., Yoneda, Y., Ohksawa, S. et al. Double-blind, placebo controlled trial of a recombinant tissue plasminogen activator in acute carotid stroke. Neurology 1991, 41 (Suppl. 1): Abst 347.
65. Zeumer, H., Freitag, H.J., Grzyska, U., Neunzig, HP. Local intra-arterial fibrinolysis in acute vertebro-basilar occlusion. Technical developments and recent results. Neuroradiology 1989, 31: 336-40.
66. del Zoppo, G.J., Poeck, K., Pessin, M.S. et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neuroi 1992, 32; 78-86.
67. Ohtaki, M., Shinya, T., Yamamura, A. et al. Local fibrinolytic therapy using superselective catheterization for patients with acute cerebral embolism within 10 hour. In: Microcirculatory Stasis in the Brain. Tomita, M., Mehediishvui, G., Rosenblum, W., Heiss, W.D., Fukuuchi, Y. (Eds.). Elsevier: Amsterdam 1993, 539-45.
68. Matsumoto, K., Satoh, K. Intra-arterial therapy in acute ischemic stroke. In: Thrombolytic Therapy in Acute Ischemic Stroke III. Yamaguchi, T., Mori, E., Minematsu, K., del Zoppo, G.J. (Eds.). Springer: Tokyo 1995, 279-87.
69. Ezura, M., Takahashi, A., Yoshimoto, T. Acute local fibrinolysis for embolic middle cerebral artery occlusion using recombinant tissue type plasminogen activator. In: Thrombolytic Therapy in Acute Ischemic Stroke III. Yamaguchi, T., Mori, E., Minematsu, K., del Zoppo, G.J. (Eds.). Springer: Tokyo 1995, 335-8.
70. von Kummer, R., Brandt, T., Muller-Kuppers, M., Hacke, W., Sartor, K. Thrombolytic therapy of basilar artery occlusion: Preconditions for recanalization and good clinical outcome. In: Thromboiytic Therapy in Acute Ischemic Stroke III. Yamaguchi, T., Mori, E., Minematsu, K., del Zoppo, G.J. (Eds.). Springer: Tokyo 343-8.
71. Higashida, R.T., Tsai, F.Y., Halbach, V.V., Barnwell, S.L., Dowd, C.F., Hieshima, G.B. Interventional neurovascular techniques in the treatment of stroke-state-of-the-art therapy. J Intern Med 1995, 237: 105-15.
72. Sasaki, O., Shigekazu, T., Koike, T., Koizumi, T., Tanaka, R. Fibrinolytic therapy for acute embolic stroke: Intravenous, intracarotid and intra-arterial local approaches. Neurosurgery 1995, 36: 246-53.
73. Ueda, T., Hatakeyama, T., Kumono, Y., Sakaki, S., Uraoka, T. Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT. Stroke 1994, 25: 298-303.
74. Barr, J.D., Mathis, J.M., Wildenhain, S.L., Wechsler, L., Jungreis, C.A., Horton, J.A. Acute stroke intervention with intra-arterial urokinase infusion. J Vasc Intervent Radiol 1994, 5: 705-13.
75. Wildenhain, S.L., Jungreis, C.A., Barr, J.D., Mathis, J.M., Wechsler, L., Horton, J.A. CT after intracranial thrombolysis for acute stroke. AJNR 1994, 15: 487-92.
76. Barnwell, S.L., Clark, W.M., Nguyen, T., O'Neil, O., Wynn, M., Coull, B. Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. AJNR 1994, 15: 1817-22.
77. Jansen, O., von Kummer, R., Forsting, M., Hacke, W., Sartor, K. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation. AJNR 1995, 16: 1977-86.
78. Brandt, T., von Kummer, R., Mullers-Kuppers, M., Hacke, W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 1996, 27: 875-81.
79. del Zoppo, G., Higashida, R.T., Furlan, A., Pessin, M.S., Gent, M., Driscoll, R.M. and the PROACT Investigators. The Prolyse in Acute Cerebral Thromboembolism Trial (PROACT): Results of 6 mg dose tier. Stroke 1996, 27: Abst 164C.
80. Mori, E. Safety, and efficacy of thrombolytic agents in acute ischemic stroke. Cerebrovasc Dis 1993, 3: 264-8.
81. del Zoppo, G.J., Pessin, M.S., Mori, E., Hacke, W. Thrombolytic intervention in acute thrombotic and embolic stroke. Semin Neurol 1991, 11: 368-84.
82. von Kummer, R., Forsting, M., Hacke, W., Sartor, K. Recanalization, infarct volume, cerebral hemorrhage and clinical outcome after intravenous recombinant tissue plasminogen activator and heparin in acute carotid territory stroke. In: Thrombolytic Therapy in Acute Ischemic Stroke II. del Zoppo, G.J., Mori, E., Hacke, W. (Eds.). Springer-Verlag: Berlin 1993, 53-8.
83. Mori, E., Yoneda, Y., Tabuchi, M. et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992, 42: 976-82.
84. Yamaguchi, T., Hayakawa, T., Kikuchi, H. for the Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator in acute thromboembolic stroke: A placebo controlled, double-blind trial. In: Thrombolytic Therapy in Acute Ischemic Stroke II. del Zoppo, G.J., Mori, E., Hacke, W. (Eds.). Springer-Verlag: Berlin 1993, 59-65.
85. Yamaguchi, T., Kikuchi, H., Hayakawa, T. for the Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute thromboembolic stroke: A randomized, double-blind, dose-comparison study of duteplase. In: Thrombolytic Therapy in Acute Ischemic Stroke III. Yamaguchi, T., Mori, E., Minematsu, K., del Zoppo, G.J. (Eds.). Sringer: Tokyo 1995, 223-9.
86. Samama, M.M., Acar, J. Thrombolytic therapy: Future issues. Thromb Haemostas 1995, 74: 106-10.
87. Simoons, M.L., de Jaegere, P., van Domburg, R., Boersma, E. Intracranial hemorrhage after thrombolytic therapy. A perspective. Z Kardiol 1982, 2: 153-6.
88. 88. Kase, C.S., O'Neal, A.M., Fisher, M., Girgis, G.N., Ordia, J.I. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. Ann Intern Med 1990, 112: 17-21.
89. Okada, Y., Yamaguchi, T., Minematsu, K. et al. Hemorrhagic transformation in cerebral embolism. Stroke 1989, 20: 598-603.
90. Fisher, M. Potentially effective therapies for acute ischemic stroke. Eur Neurol 1995, 35: 3-7.
91. Brain attack pathway and protocol. University Hospitals of Cleveland, December, 1993.
92. Wright, R.L., Ames, A. Measurement of maximal permissible cerebral ischemia and a study of its pharmacological prolongation. J Neurosurg 1964, 21: 567-74.
93. Scheinberg, P. Stroke: The way things really are. Stroke 1994, 25: 1290-4.
94. Fisher, M., Bogousslavsky, J. Evolving toward effective therapy for acute ischemic stroke. JAMA 1993, 270: 360-4.
95. Pulsinelli, W. Pathophysiology of acute ischaemic stroke. Lancet 1992, 339: 533-6.
96. Choi, D. Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev 1990, 2: 105-47.
97. Ferger, D., Krieglstein, J. Cerebral ischemia: Pharmacological bases of drug therapy. Dementia 1996, 7: 161-8.
98. 28K and ischemic damage of pyramidal cells in rat hippocampus. J Neurosci Res 1992, 31; 89-95.
99. Scheinberg, P. The biologic basis for the treatment of acute stroke. Neurology 1991, 41: 1867-73.
100. van den Kerckhoff, W., Drewers, L.R. Transfer of the Ca-antagonists nifedipine and nimodipine across the blood-brain barrier and their regional distribution in vivo. J Cereb Blood Flow Metab 1985, Suppl: 459-60.
101. Philippon, J., Grob, R., Dagreau, F., Guggiari, M., Rivieriz, M., Viars, P. Prevention of vasospasm in subarachnoid hemorrhage. A controlled study with nimodipine. Acta Neuorchir 1986, 82: 110-4.
102. 1Jan, M., Buchheit, F., Tremoulet, M. Therapeutic trial on intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. Neurosurgery 1988, 23: 154-7.
103. Kaste, M., Fogelholm, R., Erila, T. et al. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke (STIPAS). Stroke 1994, 25: 1348-53.
104. Mohr, J.P., Orgogozo, J.M., Harrison, M.J.G. et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994, 4: 197-203.
105. Heiss, W.D., Holthoff, V., Pawlik, G., Neveling, M. Effect of nimodipine on regional cerebral glucose metabolism in patients with acute ischemic stroke as measured by positron emission tomography. J Cereb Blood Flow Metab 1990, 10: 127-32.
106. Norris, J.W., Le Brun, L.H., Anderson, B.A. (The Canwin Study Group). Intravenous nimodipine in acute ischemic stroke. Cerebrovasc Dis 1994, 4: 194-6.
107. Wahlgren, N.G., MacMahon, D.G., De Keyser, J., Indredavik, B., Ryman, T. for the INWEST Study Group. Intravenous Nimodipine West European Stroke Trial of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994, 4: 204-10.
108. Gelmers, H.J., Hennerichi, M. Effect of nimodipine on acute ischemic stroke. Pooled results from five randomized trials. Stroke 1990, 21(12, Suppl): IV81-4.
109. Vorstrup Sandersen, A., Blegvad, N., Paulson, O.B. Calcium antagonist (PY 108-068) treatment may further decrease flow in ischemic areas in acute stroke. J Cereb Blood Flow Metab 1986, 6: 222-9.
110. Oczkowski, W.J., Hachinski, V.C., Bogousslavsky, J., Barneti, H.J.M., Carruthers, S.G. A double-blind, randomized trial of PY 108-068 in acute ischemic cerebral infarction. Stroke 1989, 20: 604-8.
111. Azcona, A., Lataste, X. Isradipine in patients with acute ischemic cerebral infarction: An overview of the ASCLEPIOS programme. Drugs 1990, 40 (Suppl. 2): 52-7.
112. Lataste, X., Maurer, W., Whitehead, J. and the ASCLEPIOS Study Group. Application of sequential methods to clinical trial in stroke: The ASCLEPIOS Study. 2nd World Cong Stroke (September, Washington, DC) 1992, s16.
113. Limburg, M., Hijdra, A. Flunarizine in acute ischemic stroke: A pilot study. Eur Neurol 1990, 30: 121-2.
114. Prange, H., Hargung, J., Hertel, G. et al. (The German Flunarizine Study Group). Treatment of acute stroke with flunarizine intravenous. ?? Int Conf Stroke (October, Geneva) 1991, 39.
115. Muir, K.W., Lees, K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995, 26: 503-13.
116. Wahlgren, N.G. Cytoprotective therapy for acute ischemic stroke. In: Stroke Therapy. Fisher, M. (Ed.). Butterworth-Hememann: Boston 1995, 315-50.
117. Sills, M.A., Loo, P.S. Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate. Mol Pharmacol 1989, 36: 160-5.
118. Buchan, A.M., Lesiuk, H., Barnes, K.A., Li, H., Smith, K.E., Xue, D. AMPA antagonists: Do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 1993, 24 (Suppl. 1): 1148-52.
119. Koek, W., Woods, J.H., Winger, G.D. MK-801, a proposed noncompetitive antagonist of excitatory amino acid transmission produces phencyclidine-like behavioral effect in pigeons, rats, and rhesus monkeys. J Pharmacol Exp Ther 1988, 245: 969-74.
120. Park, C.K., Nehls, D.G., Teasdale, G.M., McCulloch, J. Effect of the NMDA antagonist MK-801 on the local cerebral blood flow in focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1989, 9: 617-22.
121. Wong, E.H., Kemp, J.A., Priestly, T., Knight, A.R., Woodruff, G.N., Iversen, L.L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 1986, 83: 7104-8.
122. Albers, G.W., Saenz, P.E., Moses, J.A., Choi, D.W. Safety of and tolerance of oral dextromethorphan in patients at risk for brain ischemic stroke. Stroke 1991, 22: 1075-7.
123. Albers, G.W., Atkinson, R.P., Kelley, R.E., Rosenbaum, M.D. on behalf of the Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 1995, 26: 254-8.
124. Albers, G.W., Atkinson R, Kelley, R.E. et al. for the Dextromethorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist Ro-01-6794/706 in patients with acute ischemic stroke. Ann NY Acad Sci 1995, 765: 249-61.
125. Fisher, M. for the CNS 1102-003 Investigators. Cerestat (CNS 1102), a non-competitive NMDA antagonist in ischemic stroke patients: Dose escalating safety study. Cerebrovasc Dis 1994, 4; 245.
126. Edwards, K. and the CNS 1102-008 Study Group. Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke: Results of phase II trial. Neurology 1996, 46 (Suppl. 1): Abst 424.
127. Muir, K.W., Lees, K.R. Initial experience with remacemide hydrochloride in patients with acute ischemic stroke. 2nd Int Conf Neuroprotect Agents (August, Lake George, NY) 1994.
128. Strand, T., Wester, P.O. et al. A double blind randomized pilot trial of magnesium therapy in acute cerebral infarction. 7th Nord Meet Cerebrovasc Dis (August, Jyvaskula) 1993, 37.
129. Muir, K.W., Lees, K.R. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Ann NY Acad Sci 1995, 765: 315-6.
130. Warkins, J.C., Oleveman, H.J. Agonists and antagonists for excitatory aminoacid receptors. Trends Neurosci 1987, 10: 265-72.
131. Boast, C.A., Gerhardt, S.C., Pastor, G. et al. The N-methyl-D-aspartate antagonists CGS-19755 and CPP reduce ischemic brain damage in gerbils. Brain Res 1988, 442: 395-8.
132. Hasegawa, Y., Fisher, M., Baron, B.M., Metcalf, G. The competitive NMDA antagonist MDL 100,453 reduces infarct size after experimental stroke. Stroke 1994, 25: 1241-6.
133. Grotta, J. for the CGS19755 Study Group. Safety and tolerability of the glutamate antagonist CGS19755 in acute stroke patients. Stroke 1994, 25: 255.
134. Clark, W.M., Coull, B.M. for the CGS19755 Study Group. Randomized trial of CGS19755, a glutamate antagonist, in acute ischemic stroke. Stroke 1994, 44 (Suppl. 2): A270.
135. Coull, B.M. Randomized trial of CGS 19755, a glutamate antagonist, in acute ischemic stroke treatment. Annu Meet Amer Acad Neurol (May, Washington, DC) 1994.
136. Williams, K., Romano, C., Dichter, M.A., Molinoff, P.B. Modulation of the NMDA receptor by polyamines. Life Sci 1991, 48: 469-98.
137. Kleckner, N.W., Dingledine, R. Requirements for glycine in activation of NMDA receptors expressed in Xenopus oocytes. Science 1988, 241: 835-7.
138. Tridgett, R., Foster, A.C. Prevention of NMDA receptor-mediated neurodegeneration in the rat striatum by an antagonist at the glycine modulatory site. Br J Pharmacol 1988, 85: 890.
139. Warner, D.S., Martin, H., Ludwig, P. et al. In vivo models of cerebral ischemia: Effects of patenterally administered NMDA receptor glycine site antagonists. J Cereb Blood Flow Metab 1995, 15: 188-96.
140. Graham, S.H., Chen, J., Lan, J., Leach, M.J., Simon, R.P. Neuroprotective effect of a use dependent blocker of voltage dependent sodium channels, BW619C89, in rat MCA occlusion. J Pharmacol Exp Ther 1994, 269: 854-9.
141. Leach, M.J., Swan, J.H., Eisenthal, D., Dopson, M., Nobbs, M. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 1993, 24: 1063-7.
142. Smith, S.E., Lekieffre, D., Sowinski, P., Meldrum, B.S. Cerebroprotective effect of BW619C89 after focal or global cerebral ischemia in the rat NeuroReport 1993, 4: 1339-42.
143. Muir, K.W., Lees, K.R., Hamilton, S.J.C., George, C.F., Hobbiger, S.F., Lunnon, M.W. A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke. Ann NY Acad Sci 1995, 765: 328-9.
144. Dunwiddie, T.V. The physiological role of adenosine in the central nervous system. Int Rev Neurobiol 1985, 27: 63-139.
145. Fredholm, B.B., Dunwiddie, T.V. How does adenosine inhibit transmitter release? Trends Pharmacol Sci 1988, 9: 130-4.
146. Huber, M., Kittner, B., Hojer, C., Fink, G.R., Neveling, M., Heiss, W.D. Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke. J Cereb Blood Flow Metab 1993, 13: 526-30.
147. Tietjen, G.E., Dombi, T., Pulsinelli, W.A., Becske, T., Kugler, A.R., Mann, M.E. A double-blind, safety and tolerance study of single intravenous doses of fosphenytoin in patients with acute ischemic stroke. Neurology 1996, 46 (Suppl. 1): A424.
148. Scheller, D., Kolb, J., Szathmary, S. et al. Extracellular changes of glutamate in the peri-infarct zone: Effect of lubeluzole. J Cereb Blood Flow Metab 1995, 15 (Suppl. 1): S379.
149. Lesage, A.S., de Loore, K.L., Osikowska-Evers, B., Peeters, L., Leysen, J.F. Lubeluzole, a novel neuroprotectant, inhibits the glutamate activated NOS pathway. Soc Neurosci Abst 1994, 20: 185.
150. Diener, H.C., Hacke, W., Hennerichi, M., Radberg, J., Hantson, L., de Keyser, J. for the Lubeluzole International Study Group. Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial. Stroke 1996, 27: 76-81.
151. Squire, I.B., Lees, K.K., Pryse-Phillips, W., Kertesz, A., Bamford, J. for the Lifarizine Study Group. Efficacy and tolerability of lifarizine in acute ischemic stroke. A pilot study. Ann NY Acad Sci 1995, 765: 317-8.
152. Keinanen, K., Wisden, W., Sommer, B. et al. A family of AMPA-selective glutamate receptors. Science 1990, 299: 556-60.
153. Choi, D.W., Koh, J., Peters, S. Pharmacology of glutamate neurotoxicity in cortical cell culture: Attenuation by NMDA antagonists. J Neurosci 1988, 8: 185-96.
154. Koh, J., Goldberg, M.P., Hartley, D.M., Choi, D.W. Non-NMDA receptor-mediated neurotoxicity in cortical culture. J Neurosci 1990, 10: 693-705.
155. Meden, P., Overgaard, K., Sereghy, T., Boysen, G. Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model. J Neurosci 1993, 119: 209-16.
156. Nurse, S., Corbett, D. Neuroprotection after several days of mild, drug-induced hypothermia. J Cereb Blood Flow Metab 1996, 16: 474-80.
157. 1A agonists: A new therapeutic principal for stroke treatment. Stroke 1990, 21 (Suppl. IV): IV161-3.
158. 1A-receptor agonists on hippocampal damage after transient forebrain ischemia in the Mongolian gerbil. Stroke 1990, 21 (Suppl. IV): IV164-6.
159. Fagg, G.E., Foster, A.C. Amino acid neurotransmitters and their pathways in the mammalian central nervous system. Neuroscience 1983, 96: 701-19.
160. Barnard, E.A., Darlison, M.G., Fujita, N. et al. Molecular biology of GABA-A-receptor. Adv Exp Med Biol 1988, 236: 31-45.
161. Green, A.R., Cross, A.J., Snape, M.F., de Souza, R.J. The immediate consequences of MCA occlusion on GABA synthesis in mouse cortex and cerebellum. Neurosci Lett 1992, 138: 141-4.
162. Shuaib, A., Mazagri, R., Ijaz, S. GABA agonist muscimol is neuroprotective in repetitive transient forebrain ischemia in gerbils. Exp Neurol 1993, 123: 284-8.
163. Snape, M.F., Baldwin, H.A., Cross, A.J., Green, A.R. The effects of chlormethiazole and nimodipine on cortical infarct area after focal cerebral ischemia in the rat. Neuroscience 1993, 53: 837-44.
164. Carolei, A., Fieschi, C., Bruno, R., Toffano, G Monoganglioside GM1 in cerebral ischemia. Cerebrovasc Brain Metab Rev 1991, 3: 134-57.
165. The SASS Investigators. Ganglioside GM1 in acute ischemic stroke. Stroke 1994, 25: 1141-8.
166. Lenzi, G.L., Grigoletto, F., Gent, M. et al. for the Early Stroke Group. Early treatment of stroke with monosialoganglioside GM1. Stroke 1994, 25: 1552-8.
167. Siesjö, B.K., Agardh, C.D., Bengtsson, F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev 1989, 1: 165-211.
168. Flamm, E.S., Demopoulos, H.B., Seligman, M.L., Poser, R.G., Ransohoff, J. Free radicals in cerebral ischemia. Stroke 1978, 9: 445-7.
169. STIPAS Investigators. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994, 25: 418-23.
170. RANTTAS Investigators. Randomized trial of tirilazad in acute stroke (RANTTAS). Stroke 1996, 27: 195.
171. Peters, G.R., Hwang, L-J., Musch, B., Brosse, D.M., Orgogozo, J.M. Safety and efficacy of 6 mg/kg/day tirilazad mesylate in patients with acute ischemic stroke (TESS Study). Stroke 1996, 27: 195.
172. Garcia, J.H., Liu, K-F., Relton, J.K. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with MCA occlusion. Am J Pathol 1995, 147: 1477-86.
173. Garcia, J.H., Liu, K-F., Bree, M.P. Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral occlusion. Am J Pathol 1996, 148: 241-8.
174. Jiang, N., Moyle, M., Soule, H., Rote, W., Chopp, M. Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats. Ann Neurol 1995, 148: 241-8.
175. Polmar, S.H., Sherman, D.G. Double-blind, randomized, placebo-controlled trial of the efficacy and safety of enlimomab (anti-ICAM-1) compared to placebo administered within 6 hours of the onset of stroke symptoms, for treatment of acute ischemic stroke. Stroke 1996, 27: 177.
176. D'Oriando, K.J., Sandage, B.W. Jr. Citicoline (CDP-choline): Mechanisms of action and effects in ischemic brain injury. Neurol Res 1995, 17: 281-4.
177. Clark, W.M., Portland, O.R., Warach, S.J. for the Citicoline Study Group. Randomized dose response trial of Citicoline in acute ischemic stroke patients. Neurology 1996, 46 (Suppl. 1): A425.
178. Du, C., Hu, R., Csernansky, C.A., Hsu, C.Y., Choi, D.W. Very delayed infarction after mild focal cerebral ischemia: A role for apoptosis? J Cereb Blood Flow Metab 1996, 16: 195-201.
179. Charriaut-Mariangue, C., Margaill, I., Represa, A., Popovici, T., Plotkine, M., Ben-Ari, Y. Apoptosis and necrosis after reversible focal ischemia: An in situ DNA fragmentation analysis. J Cereb Blood Flow Metab 1996, 16: 186-94.
180. Matsushima, K., Schmidt-Kastner, R., Hakim, A.M. Genes and cerebral ischemia: Therapeutic perspectives. Cerebrovasc Dis 1996, 6: 119-27.
181. 1Fisher, M., Meadows, M.E., Do, T. et al. Delayed treatment with intravenous basic fibroblast growth factor reduces infarctsize following permanent focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1995, 15: 953-9.
182. Gross, C.E., Bednar, M.M., Howard, D.B., Sporn, M.B. Transforming growth factor-β1 reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke 1993, 24: 558-62.